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Abstract: Bone cement is widely used in surgical treatments for
the fixation for orthopaedic devices. Subsequently, 2–3% of
patients undergoing these procedures develop infections that
are both a major health risk for patients and a cost for the health
service providers; this is also aggravated by the fact that antibiot-
ics are losing efficacy because of the rising resistance of micro-
organisms to these substances. In this study, oleic acid capped
silver nanoparticles (NP) were encapsulated into Poly(methyl
methacrylate) (PMMA)-based bone cement samples at various
ratios. Antimicrobial activity against Methicillin Resistant Staph-
ylococcus aureus, S. aureus, Staphylococcus epidermidis, Acine-
tobacter baumannii was exhibited at NP concentrations as low
as 0.05% (w/w). Furthermore, the mechanical properties and
cytotoxicity of the bone cement containing these NP were
assessed to guarantee that such material is safe to be used in
orthopaedic surgical practice. VC 2014 Wiley Periodicals, Inc. J Biomed
Mater Res Part B: Appl Biomater 00B:000–000, 2014.
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INTRODUCTION
Bone cement is a biomaterial routinely used during ortho-
paedic surgeries to accomplish ﬁxation between bone and
an orthopaedic device. Microbial infections are a serious
risk associated with any type of surgical procedure; accord-
ing to the National Healthcare Safety Network data the
infection rates as a result of the total joint replacements
(TJR) surgeries are between 1.7–2% in the UK1, while it
reaches up to 2.3% in the United States2 with the highest
rate for ankle replacement (15%).3
The traditional approach to prevent infections caused by
the implantation of bone cement is through the use of anti-
biotics either through parental delivery4,5 or through release
from the bone cement itself.6–10 However, the reliance on
antibiotic therapies appears to be a time-limited solution
because of the continuing increase of microorganisms resist-
ance to these molecules.11,12 Hence, the development of
antimicrobial therapies or prophylactic treatments not based
on antibiotics is of particular interest and extremely urgent.
The utilization of nanometals, particularly silver,13 is a
promising example of such alternative approaches.
Although metal nanoparticles (NP) have been synthesized
by a variety of physical and chemical protocols, it is the reduc-
tion of metal salts that has become the standard route for their
synthesis. For instance, to prepare silver NP, ionic silver (Ag1)
contained in a salt, generally AgNO3, is reduced to metal silver
(Ag0) through a reducing agent such as HNO3/citrate,
14 Al-alk-
oxide,15 NaBH4,
16 N,N-dimethyl formamide,17 or sugars.18 The
NP can also be stabilized using chelating substances such as:
citrates,19 oleic acid,18 and glutamic acid20 or prepared with a
capping agent that allows binding of other compounds to the
NP such: glutathione,21,22 cysteine,22,23 or tiopronin.24 More-
over, silver NP of different morphologies (size and shape) can
be obtained modifying the reaction conditions.25
In this work, silver NP capped with oleic acid were prepared
using a modiﬁed Tollens method18,26 and characterized; this was
followed by their encapsulation in Poly(methyl methacrylate)
(PMMA)-based bone cement at different concentrations. The
obtained formulations of bone cements were analyzed for their
antimicrobial activity against Methicillin Resistant Staphylococcus
aureus (MRSA), S. aureus, Staphylococcus epidermidis, and Acineto-
bacter baumannii. Also cytocompatibility and material character-
isation of these bone cement materials were performed.
MATERIALS AND METHODS
Silver-oleic acid stabilized NP preparation and
characterization
Chemicals. AgNO3 (99.0%), sodium hydroxide (991%),
aqueous ammonia (NH3), oleic acid (991%), and glucose
were supplied by Sigma Aldrich.
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Synthesis of particles. The Ag NPs synthesis was performed
following a modiﬁed Tollens technique as proposed by Le
et al. (2010).18 In particular, silver nitrate (1.7 g, 0.10 mmol)
was dissolved in deionized water (100 mL), this was followed
by Ag2O precipitation in the presence of NaOH (0.62g,
0.15mmol). The obtained precipitate was ﬁltered and dis-
solved in aqueous ammonia (100 mL, 0.4%, w/w) until the
transparent solution of ½AgðNH3Þ21ðaqÞ formed. Oleic acid (2.5g,
8.9 mmol) was added drop wise into the complex with vigor-
ous stirring that was continued for 2 h at room temperature
until complete homogeneity of the reaction mixture was
achieved. Glucose (2 g, 0.11mmol) was added to the mixture
at room temperature with gentle stirring. The reduction pro-
cess of the silver complex solution (in a quartz glass) was ini-
tiated with UV irradiation (UV lamp (k 5 365 nm, 35 W). UV
treatment was carried out for 8 h under vigorous stirring
without additional heating. After 8 h of irradiation, a transpar-
ent dispersion of oleic acid-stabilized Ag NPs was obtained.
Transmission electron microscopy—size distribution. For
transmission electron microscopy (TEM) characterisation, a
4 lL droplet of NP suspension was placed on a plain
carbon-coated copper TEM grid and allowed to evaporate in
air under ambient laboratory conditions for several hours.
Bright ﬁeld TEM images were obtained using a JEOL-1010
microscope at 80 kV equipped with a Gatan digital camera.
Typical magniﬁcation of the images was 100,0003. Images
were analyzed with the computer software ImageJ and the
diameters of at least 150 particles were determined.
Encapsulation of AgNP stabilized with oleic acid into
orthopaedic bone cement and its mechanical
characterisation
The silver-oleic acid stabilized NP were mixed with PMMA-
based bone cement powder to achieve 0.1, 0.05, and 0.01%
(w/w) silver concentration in the cement. The mixture was sub-
sequently inserted into a mould at approximate dough time of
1 min. The ﬁlled mould was pressed between two glass plates
for 1 h. After the cement had hardened, it was pushed out from
the mould and stored under dark, sterile conditions at room
temperature. All assays were performed on cylindrical speci-
mens (6 mm in diameter and 12 mm in height). Prior to testing
all bone cement specimens were conditioned at 37C for 24 h.
Compression testing of PMMA-based composite bone
cement. Compression tests were undertaken on the Zwick
Roell ProLine table-top Z050/Z100 materials testing machine
according to BS ISO 5833:2002. The compression tests were
conducted at a constant cross-head speed of 20.0 mm/min to
produce a curve of displacement against load. For each speci-
men, the compressive strength of the bone cement was
determined by dividing the force applied to cause fracture by
the original cross-sectional area of the cylinder. The average
compressive strength of ﬁve specimen was calculated.
Atomic force microscope nanoindentation of PMMA-based
composite bone cement. An atomic force microscope (XE-
100 Advanced Scanning Probe Microscope from Park Sys-
tems, Korea) was used for nanoindentation tests. These
were performed using a DNSIP probe (Bruker, spring con-
stant 5 181 N/m) made of a rectangular stainless steel can-
tilever and a 3-sided diamond tip having a nominal height
of 50 lm and a nominal tip radius of 40 nm. The nanoin-
dentation was performed at various applied loads: 5, 15, 25,
35, and 45 lN. Each indentation had a holding time of 10
sec and a speed (loading rate) of 300 nN/s. For each load-
ing force at least four measurement points were chosen on
the sample. The nanoindentation tests were performed after
immersion of the bone cement specimen in phosphate
buffer solution (PBS) for 0 h, 24 h, 2 weeks, and 4 weeks.
Thus, for each silver concentration, at least 100 nanoinden-
tation cycles were conducted during this study. The mechan-
ical properties were calculated from the obtained unloading
curves according to the Oliver and Pharr method.27,28 First,
the unloading curve was ﬁtted with the following equation:
F5a ðh2hmaxÞm (1)
Where:
h is the penetration depth a, hmax, and m are ﬁtting
parameters.
Then the Young’s modulus (E) at a penetration depth
equal to hmax was calculated as:
E 5 p2
s
2
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A
p
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Where:
the stiffness (S) was given by:
S5
dF
dh

h5 hmax (3)
and the area of the indenter contact (A) was estimated as:
A524:5 hmax20:72
Fmax
s
 2
(4)
Determination of antimicrobial activity of PMMA-based
composite bone cement. The antimicrobial activity of the
bone cement samples was tested using the method adopted
from Bechert et al. (2000)29 using three Gram-positive bac-
teria: MRSA NCTC 12493, S. aureus NCIMB 9518, S. epider-
midis RP62a and one Gram negative: A. baumannii NCTC
9214. The microorganisms were cultured in Brain-Heart
Infusion (BHI) broth at 37C for 24 h. Bone cement samples
with different concentrations of silver-oleic acid capped NP
were placed into 24-well plate. The experiment was per-
formed in duplicate on three independent cultures (6 in
total). Microbial suspension of 2.5 mL were added to each
well to cover the bone cement sample and incubated at
37C for 1 h to allow microorganisms to adhere to the
cement. After 1 h the microbial suspension was removed
and the cement was rinsed three times with PBS. 1 mL of
1/10 BHI (dilution with PBS) was added in each well and
the plate was incubated at 37C for 24 h. During this phase,
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the microorganisms adhering to the cement detached. From
each well 50 lL of the bacterial suspension was transferred
in another 100-well plate (Bioscreen C accessories, Labsys-
tems, Finland) where each well contained 100 lL of fresh
BHI broth. This plate was then incubated in a plate reader
(Bioscreen C analyser, Labsystems, Finland) at 37C and the
growth curves in each well were recorded through meas-
uring optical density at 600 nm every 15 min for 24 h. The
microbial growth curves were ﬁtted with the Baranyi–Rob-
erts model [Eq. (5)–(7)] to estimate the duration of the lag
phase (k) and the maximum growth rate (lmax).
yðtÞ5y01lmaxAðtÞ2ln 11
elmaxAðtÞ21
eðymax2y0Þ
 
(5)
where:
AðtÞ5t1 1
lmax
lnðe2lmaxt1e2h02e2lmaxt2h0Þ (6)
and:
h05lmaxk (7)
In vitro cytotoxicity studies of PMMA-based composite
bone cement. Osteoblast cells (MC-3T3) were cultured in
Dulbecco’s Modiﬁed Eagle’s Medium supplemented with foe-
tal bovine serum (10%, v/v); cells were incubated at 37C
in humidiﬁed atmosphere with 5% CO2. Cells were grown
till conﬂuence, washed twice with sterile PBS, and detached
with trypsine; osteoblast cells were counted (using trypan
blue to differentiate between viable and no-viable cells) and
diluted to a concentration 105 cells/mL with fresh medium.
Bone cement samples were sterilized with 70% alcohol
and washed thrice with sterile PBS prior to use. Samples
were placed in 24-well plate containing 2 mL of osteoblast
cells suspension prepared as described earlier. Osteoblasts
were incubated with the bone cement at 37C in humidiﬁed
atmosphere with 5% CO2. After 2 days the bone cement
samples were transferred to a clean 24-well plate with
2 mL of fresh medium without red phenol. Osteoblast cells
viability was assessed using the MTT assay kit (Invitrogen,
UK). The MTT solution was prepared according to the man-
ufacturer guidelines and 10 lL added to each well. After
incubation for 2 h at 37C in humidiﬁed atmosphere with
5% CO2, the samples were transferred in a new 24-well
plate and the MTT solubilisation solution added; when full
dissolution of the crystals occurred, 100 mL of liquid was
transferred in a 96-well plate were the absorbance of each
samples was read at 570 nm. Results are presented as the
average and standard deviation of three independent bone
cement samples.
Silver release studies from PMMA-based composite bone
cement. The silver ion release from bone cement samples
was determined by inductively coupled plasma-mass spec-
troscopy analysis (Perkin Elmer Optima 2100DV OES)
against the Primar 28 element standard, which had silver at
a concentration of 100 mg/L from which subsequent dilu-
tions were made. Samples of bone cement were placed in
10 mL of fresh sterile PBS and incubated at 37C for 7 days
with a daily change of immersion liquid. Silver ion release
was measured daily.
Statistical analyses
ANOVA and t-test were performed on the results using SPSS
(12.0). For all analyses, p < 0.05 was considered statistically
signiﬁcant.
RESULTS
Example of TEM images of the silver NP are shown in Fig-
ure 1(a). All particles appeared rounded with an average
diameter of 5.3 6 2.3 nm; the cumulative distributions of
the NP diameters are presented in Figure 1(b). The distribu-
tions are closely modeled by a normal (Gaussian)
distribution.
The antimicrobial properties of the bone cements
embedded with the silver NP were determined through the
lag phase and growth rate of the MRSA, S. aureus, S. epider-
midis, and A. baumannii survivors detached from the bone
cement samples. Examples of these curves are shown in
FIGURE 1. TEM images (Bar equals to 50 nm) (a) and cumulative dis-
tribution of diameters (b) of silver-oleic acid capped NP. Solid points
are experimental data and continuous line is Gaussian fitting.
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Figure 2; while the growth rate and lag phase of the growth
curves ﬁtting with the Baranyi model are presented in Table
I. For samples without NP the OD600 of the solution starts
increasing after about 1–2 h and reached a plateau after 4 h
for S. aureus and MRSA. S. epidermidis and A. baumannii
curves exhibited a similar lag phase, but they reached a pla-
teau only after about 10–12 h. Bone cement impregnated
with 0.01% of NP returned the same growth curves as the
controls; therefore, no antimicrobial effect was detected at
this concentration. This is conﬁrmed with the results pre-
sented in Table I, where it can be seen that both the lag
phase and the growth rate at 0.01% (w/w) Ag NP did not
show signiﬁcant differences with the control samples (p >
0.05). However, the lag phase of all four bacteria increased
compared to the control samples (p < 0.05), when the con-
centration of silver in the bone cement was increased to
0.05% (w/w); while the growth rate decreased (p < 0.05).
For samples containing 0.1% (w/w) of silver NP the lag
phase increased further (p < 0.05) and for S. aureus and
MRSA no growth was evident after 24 h.
The possibility of silver NP having a cytotoxic effect was
investigated through the MTT assay on osteoblast cells (Fig-
ure 3). The presence of silver NP in bone cement did not
impact on the outcome of the enzymatic activity tested by the
MTT (p > 0.05) as all samples returned a OD540 of about 0.4
a.u. of the solution containing the dissolved formazan.
The bone cement loaded with Ag NP released Ag1 ions
to the surrounding ﬂuid (Figure 4). The cumulative
amount of Ag1 ions released from the samples containing
FIGURE 2. Examples of growth curve of S. aureus (a), MRSA (b), S. epidermidis (c), and A. baumannii (d) survivors on bone cement containing
Ag NP in different amounts (w/w). 0%, 0.01%, 0.05%, 0.1%.
TABLE I. Lag Phase and Growth Rate of the Growth Curves
of Survivals on Bone Cement Containing Ag Nanoparticles
Capped with Oleic Acid
Concentration
of Ag Nanoparticles
(%, w/w) k (h)
Growth
Rate
(h21)
S. aureus 0 2.65 6 0.10 2.10 6 0.09
0.01 2.48 6 0.31 2.18 6 0.18
0.05 14.79 6 1.54 0.85 6 0.15
0.1 > 24
MRSA 0 2.21 6 0.28 2.41 6 0.23
0.01 2.38 6 0.20 2.37 6 0.21
0.05 12.08 6 1.78 0.81 6 0.10
0.1 > 24
S. epidermidis 0 3.42 6 0.49 0.74 6 0.03
0.01 3.14 6 0.10 0.66 6 0.06
0.05 4.91 6 0.32 0.53 6 0.06
0.1 6.75 6 0.33 0.28 6 0.06
A. baumannii 0 2.93 6 0.30 0.50 6 0.08
0.01 3.93 6 0.47 0.57 6 0.04
0.05 4.20 6 0.04 0.47 6 0.02
0.1 9.81 6 0.43 0.55 6 0.03
Mean 6 standard deviation
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0.05 and 0.1% of silver NP increased monotonically from
day 1 to day 7 for all samples and no difference was
detected between the two (p > 0.05). The bone cement
containing 0.01% of Ag NP released smaller amount of sil-
ver ions than the other samples and the concentration of
Ag1 did not increase after 3 days [Figure 4(a)]. The corre-
sponding kinetics of silver ions released is shown in Fig-
ure 4(b) where it is evident that the release is faster at
the beginning of the contact with ﬂuid and slowly
decreases with time.
Figure 5 shows the changes of the calculated Youngs mod-
ulus over a 4 week period for the different concentrations of
silver NP determined through nanoindentation tests. For a
given concentration of silver NP, Young’s moduli generally
exhibited consistent values on the surface and in the bulk of
the samples; bone cement specimen containing silver NP at
low concentration (0.01%, w/w) displayed Young moduli not
dissimilar from the control samples irrespectively of the
immersion time in PBS. The immersion in PBS did not affect
the Young moduli measured for the control samples and for
bone cement containing 0.01% silver NP. At higher silver NP
concentrations (0.05 and 0.1%, w/w), the Young moduli
determined for the bone cement samples were higher than
the control just after preparation (t 5 0 h); this difference
slowly disappeared after immersion in PBS.
The amount of ﬂuid absorbed by the bone cements
resulted in an augmentation of the weight of the samples
(Figure 6). In particular, this weight increased signiﬁcantly
during the ﬁrst 2 weeks and after that, the amount of ﬂuid
in the samples remained stable. No difference in these
results was observed between the different concentrations
of silver NP encapsulated in bone cement over time.
The mechanical properties of the bone cement with sil-
ver NP embedded were assessed through the compression
strength (Figure 7) over period of 3 months. Bone cement
without any NP had compression strength of 98 6 9 MPa,
while the presence of these NP did not have a signiﬁcant
impact of the resistance to compression compared to con-
trol samples without NP (p > 0.05). Also no changes in
compression strength were observed after 3 months in PBS
(p > 0.05).
DISCUSSION
A synthesis method using the Tollens process has been pro-
posed for synthesizing Ag NPs with controlled size.26 The
basic reaction in this process involves the reduction of a sil-
ver ammonia solution by using either aldehydes or reducing
sugars.30 In comparison with other Tollens methods, that
require the use of toxic solvents and highly reactive
chemical-reducing agents, this technique is simple and inex-
pensive. The antimicrobial activity of the silver NP used in
this work was assessed through the duration of the lag
phase of the growth curve displayed by the bacteria remain-
ing on the bone cement after contact; as described in
Bechert et al. (2000)29 and Prokopovich et al. (2013),24 this
lag phase is more correctly denoted as “apparent lag phase”
and is related to the number of living cells surviving on the
bone cement samples, the higher the bacteria concentration
the shorter the apparent lag phase.
The results (Table I) presented here demonstrated that
the lowest concentration of NP (0.01%, w/w) is ineffective
against all pathogenic species used in this study. Increasing
the concentration returned progressively higher levels of
FIGURE 4. Releases of silver ions from bone cement. Concentration in
the release medium (a) and cumulative release (b). (•) 0.01%, ()
0.05%, and (!) 0.1%.
FIGURE 3. MTT assay for bone cement containing NP.
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antimicrobial activity with differences between strains. S.
aureus and MRSA were totally removed by silver NP at con-
centrations of 0.1%, w/w, while the longer “apparent lag
phase” of MRSA with concentrations of 0.05% highlighted
the greater vulnerability of MRSA to silver NP. Our results
also suggested that S. epidermidis and A. baumannii were
more resistant to silver NP than both S. aureus strains used
in this work as little effect was detected in bone cement
samples containing 0.05%, w/w of silver NP and living cells
were detected in samples impregnated with silver NP at a
concentration of 0.1%, w/w (Figure 2). However, the
observed reduction of A. baumannii and S. epidermidis
proved that the encapsulation of oleic acid capped silver NP
in bone cement can be a viable approach to prevent infec-
tions offset. The pathogens tested in our work are represen-
tative of the most commonly found causes of infections in
postoperatory surgeries,31,32 particularly A. baumannii is
receiving a lot of attention in virtue of its resistance to
many of the drugs generally utilized to treat orthopaedic
surgeries related infections.33 Some of S. epidermidis strains
also possess high resistance to gentamicin; in addition,
some S. epidermidis isolates have shown resistance to Methi-
cillin (so called Methicillin Resistant S. epidermidis or MRSE)
and the strain used in this work (RP62a, also known as
ATCC 35984) is one of these.34
The high antimicrobial activity of bone cement contain-
ing oleic acid capped silver NP against the most common
source of postoperatory infections, which are also increas-
ingly resistant to the routinely used antibiotics to treat
them, highlights the signiﬁcant beneﬁt of such approach in
preventing infection offset in patients undergoing surgeries
requiring bone cement.
Another form of silver NP was used by Alt et al.
(2004),35 however, the properties of the nanomaterial used
in that study were not characterized further than the aver-
age size (5–50 nm), furthermore no description of the syn-
thetic method was given and the NP were generally referred
as “nanosilver.” Growth of MRSA and MRSE was not pre-
vented by PMMA bone cement containing nanosilver at con-
centration of 0.1%, w/w,35 hence that type of silver NP was
not as effective as oleic acid capped silver NP because such
concentration is capable of reducing the number of viable
cells of these two species (Figure 2). Other silver NP (tio-
pronin capped and in two different sizes) were used in pre-
vious studies to confer antimicrobial activity to PMMA bone
cement and they did show a total reduction of living MRSA
at concentrations as low as 1%, w/w even for the most
active type.24 Therefore, the silver NP used here, capped
with oleic acid, appeared to display higher lethality toward
microorganisms compared to tiopronin capped ones. Not
FIGURE 5. Young modulus of bone cement containing NP determined through nanoindentation tests after immersion in PBS for 0 h (a), 24 h
(b), 2 weeks (c), and 4 weeks (d). (•) 0%, (!) 0.01%, () 0.05%, and () 0.1%.
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only silver NP have been encapsulated in bone cement to help
infections offset; other nanomaterials such as: chitosan NP,36
quaternised chitosan derivative,34 and mesoporous silica
NP37 along with Nisin-F (a bacteriocin)38 and silver ions39
were used with various degree of success. However, in these
studies the amount of antimicrobial compound added to the
bone cement was signiﬁcantly higher than 0.05 and 1%, w/w
used here, in some cases up to 20%, w/w34 and 30%.36 Such
differences starkly highlight the potent antimicrobial activity
of the oleic acid capped silver NP compared to other antibac-
terial compounds.
Many properties of the NP are important in determining
the antimicrobial activity, for example: size and shape have
been linked to different bactericidal activity40; furthermore,
the amount and chemical nature of capping agent have also
been implicated in varying antimicrobial activity among
NP.24 A higher percentage of capping agent reduced the NP
capacity of preventing bacteria growth,24 however, the dif-
ferent synthetic conditions used to obtain NP with dissimi-
lar quantity of capping agent also resulted in NP of different
mean size, hence the impact of size and organic fraction
present in the NP (capping agent) could not be univocally
assessed. Interestingly, the size of the tiopronin capped NP
that did not exhibited any antimicrobial activity (about 5
nm)24 is similar to the size of NP prepared here, thus, it can
be said that size alone is not a unique factor granting anti-
microbial activity to silver NP. In addition, it has been sug-
gested that the amount of silver ions released in the
surrounding media by silver NP is not the only mechanism
of action of such nanomaterials for inactivating microorgan-
isms.22,24 The results presented here (Figure 4) coupled
with those presented in Prokopovich et al. (2013)24 further
strengthen such conclusion as the overall amount of silver
ions released by bone cement containing oleic acid capped
silver NP is about 10 folds lower than that of tiopronin
capped silver NP.24 This lower silver ion release is probably
as consequence of the lower NP concentration in bone
cement used in this work.
Small amounts of silver are ingested daily, (minority)
some is resorbed by the intestine, the rest (majority) is
excreted by the liver; in vivo concentrations below 200 ppb
are considered normal.39 The amounts released (2–3 lg/
day) from the bone cement in this will likely raise the blood
silver level in an adult by less than 20 ppb (even when 10
folds bigger bone cements quantities are used leading to
20–30 lg/day and assuming 2–3 L of blood, the increase of
Ag1 is 10–15 lg/L (ppb); hence we can exclude systemic
toxic effects.
Nanoindentation experiments revealed that the mechani-
cal properties of bone cement are quite uniform from the
superﬁcial to the bulk area; this also suggests that the NP are
homogeneously distributed in the samples. In addition to the
nanoindentation experiments, the determination of the com-
pression strength revealed that the materials properties of
the bone cement, irrespectively of the presence of oleic acid
capped silver NP, decreased with time during immersion in
ﬂuids. This is attributed to the uptake of water, as determined
in Figure 6; such phenomenon occurs in the ﬁrst few days
and the mass of water containing in the bone cement remains
stable after this initial period of time. The water uptake
accounting for the change in mechanical properties appeared
validated by the simultaneous decrease in Young’s modulus
as measured through nanoindentation after 24 h and 2 weeks
of contact with PBS and increase in water content in the bone
cement. After the ﬁrst 2–3 weeks, the water content reached
a plateau and no further changes were detected in Young’s
modulus through nanoindentation.
To be adopted as a feasible medical device that prevents
infections, bone cement containing NP must also possess
other properties such as satisfactory mechanical and cyto-
compatibility characteristics. As our results proved, no detri-
mental effect resulted from the presence of oleic acid
capped silver NP on the mechanical properties of PMMA
bone cement determined through nanoindentation and mac-
rocompression strength (Figures 5 and 7). Moreover, the
cytocompatibility of the bone samples with encapsulated
oleic acid capped silver NP was no different than standard
PMMA-based bone cement (Figure 3).
FIGURE 6. Percentage of weight variation of bone cement containing
NP nanoindentation after immersion in PBS (a). (•) 0%, (!) 0.01%,
() 0.05%, and () 0.1%.
FIGURE 7. Compression strength of bone cement containing NP after
0 h (black column) and 3 months (light gray column)
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CONCLUSIONS
Silver NP capped with oleic acid can confer antimicrobial
properties to bone cement without inﬂuencing its mechani-
cal properties and cytocompatibility.
Concentration of NP as low as 0.05%, w/w allowed a
signiﬁcant reduction of the number of microorganisms
(MRSA, S. aureus, S. epidermidis, and A. baumannii) associ-
ated to bone cement and orthopaedic surgery related infec-
tions. These pathogens are known to be resistant to some
antibiotics commonly used in the treatment and prevention
of postoperatory infections.
This work demonstrated the feasibility of developing anti-
microbial bone cement through its impregnation with Ag NP
capped with oleic acid offering an alternative to the reliance
on antibiotics. As such molecules are quickly losing efﬁcacy
through microorganisms developing resistance, a novel solu-
tion surpassing this approach to infection is greatly needed.
REFERENCES
1. Ridgeway S, Wilson J, Charlet A, Kafatos G, Pearson A, Coello R.
Infection of the surgical site after arthroplasty of the hip. J Bone
Joint Surg Br 2005;87-B:844–850.
2. Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K,
Morrell G, Dudeck MA, Pollock DA, Horan TC. National Healthcare
Safety Network (NHSN) report: Data summary for 2006 through
2008, issued December 2009. Am J Infect Control 2009;37:783–805.
3. Gougoulias N, Khanna A, Maffulli N. How successful are current
ankle replacements?: A systematic review of the literature. Clin
Orthop Relat Res 2010;468:199–208.
4. Meehan J, Jamali AA, Nguyen H. Prophylactic antibiotics in hip
and knee arthroplasty. J Bone Joint Surg Am 2009;91A:2480–2489.
5. Tyllianakis ME, Karageorgos AC, Marangos MN, Saridis AG,
Lambiris EE. Antibiotic prophylaxis in primary hip and knee
arthroplasty comparison between cefuroxime and two specific
antistaphylococcal agents. J Arthroplasty 2010;25:1078–1082.
6. Kittinger C, Marth E, Windhager R, Weinberg A, Zarfel G, Baumert
R, Felisch S, Kuehn KD. Antimicrobial activity of gentamicin pal-
mitate against high concentrations of Staphylococcus aureus. J
Mater Sci Mater Med 2011;22:1447–1453.
7. Kaplan L, Kurdziel M, Baker KC, Verner J. Characterization of
daptomycin-loaded antibiotic cement. Orthopedics 2012;35:e503–e509.
8. van de Belt H, Neut D, Schenk W, van Horn JR, van der Mei HC,
Busscher HJ. Staphylococcus aureus biofilm formation on differ-
ent gentamicin-loaded polymethylmethacrylate bone cements.
Biomaterials 2001;22:1607–1611.
9. Ofluoglu EA, Bulent E, Derya AM, Sancar BY, Akin G, Bekir T,
Erhan E. Efficiency of antibiotic loaded polymethylmethacrylate
rods for treatment of the implant-related infections in rat spine. J
Spinal Disord Tech 2012;25:E48–E52.
10. Nowinski RJ, Gillespie RJ, Shishani Y, Cohen B, Walch G,
Gobezie R. Antibiotic-loaded bone cement reduces deep infection
rates for primary reverse total shoulder arthroplasty: a retrospec-
tive, cohort study of 501 shoulders. J Shoulder Elbow Surg 2012;
21:324–328.
11. Montanaro L, Speziale P, Campoccia D, Ravaioli S, Cangini I,
Pietrocola G, Giannini S, Arciola CR. Scenery of Staphylococcus
implant infections in orthopedics. Future Microbiol 2011;6:1329–1349.
12. Zilberberg MD, Shorr AF. Secular trends in gram-negative resist-
ance among urinary tract infection hospitalizations in the United
States, 2000-2009. Infect Control Hosp Epidemiol 2013;34:940–946.
13. Pathak SP, Gopal K. Evaluation of bactericidal efficacy of silver
ions on Escherichia coli for drinking water disinfection. Environ
Sci Pollut Res Int 2012;19:2285–2290.
14. Kamat PV, Flumiani M, Hartland GV. Picosecond dynamics of sil-
ver 423 nanoclusters. Photoejection of electrons and fragmenta-
tion. J Phys Chem B 1998;102:3123–3128.
15. Jana D, De G. Spontaneous generation and shape conversion of
silver nanoparticles in alumina sol, and shaped silver nanoparticle
incorporated alumina films. J Mater Chem 2011;21:6072–6078.
16. Vasilev K, Sah VR, Goreham RV, Ndi C, Short RD, Griesser HJ.
Antibacterial surfaces by adsorptive binding of polyvinyl-
sulphonate-stabilized silver nanoparticles. Nanotechnology 2010;
21:215102.
17. Deng Y, Sun Y, Wang P, Zhang D, Jiao X, Ming H, Zhang Q, Jiao
Y, Sun X. Nonlinear optical properties of silver colloidal solution
by in situ synthesis technique. Curr Appl Phys 2008;8:13–17.
18. Le AT, Tam LT, Tam PD, Huy PT, Huy TQ, van Hieu N, Kudrinskiy
AA, Krutyakov YA. Synthesis of oleic acid-stabilized silver nano-
particles and analysis of their antibacterial activity. Mat Sci Eng C
2010;30:910–916.
19. Henglein A, Giersig M. Formation of colloidal silver nanoparticles:
Capping action of citrate. J Phys Chem B 1999;103:9533–9539.
20. Stevanovic M, Kovacevic B, Petkovic J, Filipic M, Uskokovic D.
Effect of poly-alpha, gamma, L-glutamic acid as a capping agent
on morphology and oxidative stress-dependent toxicity of silver
nanoparticles. Int J Nanomed 2011;6:2837–2847.
21. Le Guevel X, Spies C, Daum N, Jung G, Schneider M. Highly fluo-
rescent silver nanoclusters stabilized by glutathione: A promising
fluorescent label for bioimaging. Nano Res 2012;5:379–387.
22. Amato E, Diaz-Fernandez YA, Taglietti A, Pallavicini P, Pasotti L,
Cucca L, Milanese C, Grisoli P, Dacarro C, Fernandez-Hechavarria
JM, Necchi V. Synthesis, characterization and antibacterial activ-
ity against gram positive and gram negative bacteria of biomi-
metically coated silver nanoparticles. Langmuir 2011;27:9165–
9173.
23. Perni S, Hakala V, Prokopovich P. Biogenic synthesis of silver
nanoparticles capped with L-cysteine. Colloids Surf A 10.1016/
j.colsurfa.2013.09.034. Forthcoming.
24. Prokopovich P, Leech R, Carmalt CJ, Parkin IP, Perni S. A novel
bone cement impregnated with silver-tiopronin nanoparticles: Its
antimicrobial, cytotoxic and mechanical properties. Int J
Nanomed 2013;8:2227–2237.
25. Dong X, Ji X, Wu H, Zhao L, Li J, Yang W. Shape control of silver
nanoparticles bt stepwise citrate reduction. J Phys Chem C 2009;
113:6573–6576.
26. Yin Y, Li ZY, Zhong Z, Gates B, Xia Y, Venkateswaran S. Synthe-
sis and characterization of stable aqueous dispersions of silver
nanoparticles through the Tollens process. J Mater Chem 2002;
12:522–527.
27. Oliver WC, Pharr GM. An improved technique for determining
hardness and elatic modulus using load and displacement sens-
ing indentation experiments. J Mater Res 1992;7:1564–1583.
28. Prokopovich P, Perni S, Hall RM, Fisher J. Spatial variation of
wear on charite lumbar discs. Acta Biomater 2011;7:3914–3926.
29. Bechert T, Steinrucke P, Guggenbichler JP. A new method for
screening anti-infective biomaterials. Nat Med 2000;6:1053–1056.
30. Panacˇek A, Kvitek L, Prucek R, Kolar M, Vecˇerova R, Pizurova N,
Sharma VK, Nevecˇna T, Zboril R. Silver colloid nanoparticles: syn-
thesis, characterization, and their antibacterial activity. J Phys
Chem B 2006;110:16248–16253.
31. Grosso MJ, Sabesan VJ, Ho JC, Ricchetti ET, Iannotti JP. Reinfec-
tion rates after 1-stage revision shoulder arthroplasty for patients
with unexpected positive intraoperative cultures. J Shoulder
Elbow Surg 2012;21:754–758.
32. Sorlı L, Puig L, Torres-Claramunt R, Gonzalez A, Alier A, Knobel
H, Salvado M, Horcajada JP. The relationship between microbiol-
ogy results in the second of a two-stage exchange procedure
using cement spacers and the outcome after revision total joint
replacement for infection: the use of sonication to aid bacteriolog-
ical analysis. J Bone Joint Surg Br 2012;94:249–253.
33. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii:
Epidemiology, #antimicrobial |resistance, and treatment options.
Clin Infect Dis 2008;46:1254–1263.
34. Tan H, Peng Z, Li Q, Xu X, Guo S, Tang T. The use of quaternised
chitosan-loaded PMMA to inhibit biofilm formation and downreg-
ulate the virulence-associated gene expression of antibiotic-
resistant staphylococcus. Biomaterials 2012;33:365–377.
35. Alt V, Bechert T, Steinr€ucke P, Wagener M, Seidel P, Dingeldein
E, Domann E, Schnettler R. An in vitro assessment of the
8 PROKOPOVICH ET AL. ANTIMICROBIAL ACTIVITY OF BONE CEMENT WITH SILVER NANOPARTICLES
antibacterial properties and cytotoxicity of nanoparticulate silver
bone cement. Biomaterials 2004;25:4383–4391.
36. Shi Z, Neoh KG, Kang ET, Wang W. Antibacterial and mechanical
properties of cement impregnated with chitosan nanoparticles.
Biomaterials 2006;27:2440–2449.
37. Shen SC, Ng WK, Shi Z, Chia L, Neoh KG, Tan RBH. Mesoporous
silica nanoparticles-functionalized poly(methyl methacrylate)-
basde bone cement for effective antibiotics delivery. J Mater Sci
Mater Med 2011;22:2283–2292.
38. Van Staden AD, Brand AM, Dicks LMT. Nisin F-loaded brushite
bone cement prevented the growth of Staphylococcus aureus in
vivo. J Appl Microbiol 2012;112:831–840.
39. Ewald A, H€osel D, Patel S, Grover LM, Barralet JE, Gbureck U. Sil-
ver-doped calcium phosphate cements with antimicrobial activity.
Acta Biomater 2011;7:4064–4070.
40. Sadeghi B, Garmaroudi FS, Hashemi M, Nezhad HR, Nasrollahi A,
Ardalan S, Ardalan S. Comparison of the anti-bacterial activity on
the nanosiver shapes: Nanoparticles, nanorods and nanoplates.
Adv Powder Tech 2012;23:22–26.
ORIGINAL RESEARCH REPORT
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH B: APPLIED BIOMATERIALS | MONTH 2014 VOL 00B, ISSUE 00 9
